

Ynto S De Boer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4342922/publications.pdf>

Version: 2024-02-01

26
papers

1,912
citations

471509

17
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

2755
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Established and novel therapeutic options for autoimmune hepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 315-326. | 8.1 | 17 |
| 2 | Drug withdrawal in patients with autoimmune hepatitis in long-term histological remission: A prospective observational study. <i>European Journal of Internal Medicine</i> , 2021, 90, 30-36. | 2.2 | 5 |
| 3 | Seroprevalence of Hepatitis E Virus in Autoimmune Hepatitis Patients in the Netherlands. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 9-13. | 0.9 | 35 |
| 4 | The risk of liver cancer in autoimmune liver diseases. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986191. | 3.2 | 23 |
| 5 | Adverse events related to low dose corticosteroids in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1120-1126. | 3.7 | 42 |
| 6 | Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1616-1624.e2. | 4.4 | 31 |
| 7 | 17 β -Hydroxysteroid Dehydrogenase 13 is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 1504-1519. | 7.3 | 200 |
| 8 | Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 940-947.e2. | 4.4 | 36 |
| 9 | TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes. <i>Gastroenterology</i> , 2018, 155, 1923-1935.e8. | 1.3 | 11 |
| 10 | Real-world management of juvenile autoimmune liver disease. <i>United European Gastroenterology Journal</i> , 2018, 6, 1032-1038. | 3.8 | 10 |
| 11 | Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 761-767. | 3.7 | 21 |
| 12 | Letter: tacrolimus may be hazardous in decompensated autoimmune liver disease with hyperbilirubinemia—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1568-1569. | 3.7 | 0 |
| 13 | Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 103-112.e2. | 4.4 | 144 |
| 14 | Expert clinical management of autoimmune hepatitis in the real world. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 723-732. | 3.7 | 66 |
| 15 | Herbal and Dietary Supplement-Induced Liver Injury. <i>Clinics in Liver Disease</i> , 2017, 21, 135-149. | 2.1 | 58 |
| 16 | Auto immune hepatitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 4651. | 3.3 | 39 |
| 17 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1845-1846. | 4.4 | 4 |
| 18 | Assessment of the histopathological key features in autoimmune hepatitis. <i>Histopathology</i> , 2015, 66, 351-362. | 2.9 | 68 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. <i>Genes and Immunity</i> , 2015, 16, 247-252. | 4.1 | 96 |
| 20 | Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. <i>Gastroenterology</i> , 2015, 148, 1340-1352.e7. | 1.3 | 646 |
| 21 | Seroprevalence of celiac disease in patients with autoimmune hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1104-1107. | 1.6 | 29 |
| 22 | Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1. <i>Gastroenterology</i> , 2014, 147, 443-452.e5. | 1.3 | 268 |
| 23 | Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 640-646. | 3.7 | 44 |
| 24 | Cytotoxic T Lymphocyte Antigenâ€“4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis. <i>Liver International</i> , 2013, 33, 1039-1043. | 3.9 | 15 |
| 25 | Letter: allopurinol coâ€“therapy is safe and effective in autoimmune hepatitis â€“ authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 920-920. | 3.7 | 1 |
| 26 | A Case of Autoimmune Hepatitis and Bisphosphonate-Related Osteonecrosis of the Jaw. <i>Case Reports in Gastroenterology</i> , 2012, 6, 309-313. | 0.6 | 3 |